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Introduction
Non-small cell lung cancer (NSCLC) is the leading cause 
of cancer-related death across the world (1). Over 50% of 
these patients present metastatic disease at diagnosis, while 
many others develop metastatic dissemination during their 
course of disease and about 20% of these patients develop 
brain metastases. 
Median survival for patients with stage IV NSCLC 
treated with chemotherapy alone is between 8 and 
11 months (2). Brain metastases development represents 
a negative prognostic factor and median survival in this 
subgroup of patients is 7 months (3,4).
Hellman and Weichselbaum defined the oligometastatic 
state as an intermediate clinical state between locoregionally 
confined and widespread cancer (5). Since 1995 it has been 
hypothesized that these patients with limited metastatic foci 
may experience longer survival and, in rare cases, potential 
cure following comprehensive tumor ablation.
In the last two decades a number of studies evaluating 
the role of locally ablative therapies [i.e., surgical resection 
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(SR), and stereotactic radiosurgery, (SRS)] for limited 
metastatic foci have been performed (6,7). Patients with 
synchronous brain oligometastases represent a population 
that can benefit from aggressive locoregional treatments. 
SR, SRS and whole-brain radiotherapy (WBRT) are the 
main therapeutic options (8-10).
The treatment of single metastases with different 
localization than brain is controversial but several reports 
have shown longer survivals in this subgroup of patients 
treated with aggressive locoregional treatments (11-15).
We present in this report five cases of oligometastatic 
NSCLC patients experiencing unexpected long survival 
after aggressive locoregional treatment of their metastatic 
districts. 
Case presentations
The median age of the patients at diagnosis was 53.6 years 
(range, 38–64 years). Clinical and pathological features of 
the patients are reported in Table 1. 
These patients have been treated at Sant’Andrea Hospital 
of Rome between May 2009 and April 2016. For three of 
them, cancer was diagnosed during the hospitalization at 
the Emergency Department (ED) for symptoms caused 
by brain metastases. These cases were immediately treated 
with neurosurgical intervention.
Al l  pat ients  had brain metastases .  We def ined 
synchronous if the metastases occurred within 2 months 
from the diagnosis of the primary tumor. The disease 
of this subgroup of patient was considered biologically 
more aggressive. We chose 2 months for the definition of 
“synchronous metastases” according to previous published 
data and also because of logistical concerns relative to the 
SEER registry process. 
Cancer staging was done according to TNM 7th edition. 
All the patients still undergo clinical and radiological 
[Computed Tomography (CT) scan, brain magnetic 
resonance imaging (MRI)] follow-up every 6 months.
All patients are still alive, and the median overall survival 
(OS) is 49 months (range, 36–83 months).
Progression-free survival (PFS) was defined as the time 
from the first SR to the first radiological evidence of disease 
progression.
OS was defined as the time from diagnosis until death 
from any cause.
Survival data were calculated from the day of first 
treatment of either the primary tumor or metastatic lesions 
for patients with synchronous metastases, and from the day T
ab
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of first treatment of oligometastatic disease for patients with 
metachronous metastases.
Written informed consent was obtained from all the 
patients for publication of this case series.
Case 1
A 58-year-old, heavy smoker (45 pack-years), Caucasian 
male was admitted to the ED for speech impairment and 
tonic-clonic seizures on April 2013. A brain MRI revealed a 
12 mm left fronto-subcortical lesion with associated edema. 
A total body CT scan showed a 10 mm nodule in the right 
lung. An urgent SR of the brain mass was performed. An 
atypical resection of the middle lobe of the right lung was 
performed three weeks later. The histological examinations 
showed a brain metastasis of lung adenocarcinoma (ADK) 
[TTF-1+, CK7+, EGFR wild type (wt) and rearrangement 
of ALK] and a chondroid hamartoma of the lung, 
respectively. From August 2013 to January 2015 the patient 
received a first line treatment with platinum and pemetrexed 
for 6 cycles followed by maintenance pemetrexed for a 
further 6 months. Since subsequent total body CT scan 
didn’t show evidence of disease, the patient started the 
follow-up with an OS of 36 months.
Case 2
On March 2012, a 59-year-old Caucasian male, heavy 
smoker (42 pack-years) was admitted to the ED for balance 
disorder. A brain MRI showed a 15 mm cerebellar lesion. An 
urgent cerebral surgery was performed and the histological 
and immunohistochemistry features suggested a metastasis 
of NSCLC ADK TTF-1+. A CT scan revealed a mass in 
the right lung and in April 2012 the patient underwent a 
right upper lobectomy with systematic lymphadenectomy for 
stage IV grade 3 lung ADK (pT2a pN0 M1b, EGFR wt, no 
ALK rearrangement). There was no radiological evidence of 
disease after surgery. From July 2012 to October 2012 the 
patient received 4 cycles of platinum-based chemotherapy. 
There is no clinical and radiological evidence of disease 
recurrence so far, with an OS of 49 months.
Case 3
A 38-year-old, never smoker, Caucasian female underwent 
a left lower lobectomy and systematic lymphadenectomy 
on March 2012 for stage IIIA NSCLC ADK (pT3 pN2 
Mx, EGFR wt, no rearrangement of ALK and ROS-1). 
On April 2012 she came for a visit at our department and 
we decided to complete the staging with a brain MRI. 
The exam showed the presence of two brain metastases. 
Between May and September 2012, she received 6 cycles of 
platinum based chemotherapy and she underwent SRS of 
the brain metastases. On March 2013 brain MRI showed 
new metastases and the patient underwent SRS and whole 
brain radiotherapy (WBRT). At April 2016 the disease is 
still under control and the OS is 49 months. 
Case 4
A 49-year-o ld  Caucas i an  f ema le ,  heavy  smoker 
(36 pack-years) was admitted to the ED with seizures and 
hypoesthesia of the right arm on December 2010. A total 
body CT scan showed a brain lesion and a left lung mass. 
The patient underwent craniotomy with total excision of the 
brain lesion first: the histological exam revealed a metastatic 
NSCLC TTF-1+ CK7+. The patient subsequently underwent 
left upper lobectomy with systematic lymphadenectomy. 
Histological analysis showed a sarcomatoid lung cancer (pT2 
pN0 M1b). On February 2011, a brain MRI showed three 
new lesions, and so she performed SRSs. From March to July 
2011, she received 6 cycles of platinum based chemotherapy. 
On February 2012, a total body CT scan revealed an increase 
in dimension of the frontal brain lesion so she underwent a 
second cerebral surgery for mass removal. The histological 
examination showed necrosis and inflammations, with no 
evidence of cancer tissue. Afterwards, she continued the 
radiological and clinical follow-up. The patient is still alive and 
the OS is 65 months.
Case 5
A 64-year-old Caucasian female, never smoker, underwent 
a left lower lobectomy on May 2009 for stage IA lung ADK 
(pT1 pN0 G3, EGFR wt). A PET scan performed after 
surgery was negative. According to the stage of disease the 
patient did not undergo adjuvant treatment. On February 
2010 a total body CT scan and a brain MRI showed the 
presence of one left frontal brain metastasis. The patient 
underwent a SRS and then she started radiological and 
clinical follow-up. At April 2016 the patient is still alive 
with no evidences of disease and the OS is 83 months.
Discussion
An increasing interest in oligometastatic condition has 
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been observed in scientific literature since this condition 
for NSCLC has been defined in 1995 by Hellman and 
Weichselbaum (5). Many reports demonstrate that this 
subgroup of patients may experience a long survival or even 
healing (16,17). Nevertheless, only one clinical randomized 
trial has been published so far, and the management remains 
controversial. However, local therapies aimed to eradicate 
the disease seem to be the most reliable strategies (16). 
A recent systematic review published by Ashworth and 
colleagues, analyzing 49 reports and 2,176 oligometastatic 
NSCLC patients, showed highly variable results in terms 
of survival (18). In fact, in this report, OS ranges between 
5.9 and 52 months (median 14.8 months) and time to 
progression (TTP) from 4.5 to 23.7 months (median 
12 months). In particular, they observed a longer survival 
(19 months) in patients with the primary tumor controlled 
by local treatments. The longest survival has been reported 
in patients with mixed metastatic sites, while patients with 
adrenal gland metastases showed the shortest survival (18). 
The same group of researchers published in 2014 
an individual patient data metanalysis, on 757 NSCLC 
patients with 1–5 metastases (19). Both primary tumor 
and metastatic sites were treated with surgery. Twenty six 
months of median OS and 11 months of median PFS were 
observed. The authors divided the patients into three classes 
of prognosis: low risk, including patients with metachronous 
metastases; intermediate risk, including patients with 
synchronous metastases and no nodal involvement; high 
risk, including patients with synchronous metastases and 
nodal involvement (N1–N2). The 5-year OS were 47.8%, 
36.2% and 13.8%, respectively. Other prognostic factors 
were: primary tumor (T) stage; histology (better prognosis 
for ADK); presence of brain or lung metastases and surgical 
treatment of the T (19). 
Niibe and colleagues proposed another classification 
(Niibe-Onishi-Chang classification) for oligometastatic 
patients in 2013. This classification divided the patients 
in favorable, intermediate and unfavorable prognosis, 
according to the timing of metastases occurrence 
(synchronous or metachronous), the number and the 
location of metastatic sites (20).
Although the traditional management for metastatic 
NSCLC contemplates only palliative treatments, recent 
data show that surgery of the primary tumor leads to 
a better survival in patients with NSCLC and brain 
metastases (8,17,21,22).
Iwasaki and colleagues demonstrated that patients that 
underwent lung and brain surgery experience a longer 
survival than patients who underwent resection of the lung 
lesion only (23). American College of Chest Physicians 
(ACCP) Guidelines suggest SR of the brain metastasis 
followed by WBRT and adjuvant chemotherapy as standard 
of care for patients with a single brain metastatic focus (24).
The management of multiple brain metastases is more 
controversial. SRS may be the preferable option in these 
cases (25). 
Interestingly, recent data, mainly reported as case 
reports, showed a tumor regression at non-irradiated 
sites. This effect, called “abscopal”, could be mediated by 
immune system, by enhancing T cells function, inducing 
immunogenic cells’ death and improving antigen expression 
and presentation (26,27).
The concern in  understanding the  b io logy of 
oligometastatic cancer is lately increasing. It is commonly 
accepted that metastatic progression is a multi-step 
process. Two hypotheses to explain the differences between 
oligometastases and polymetastases have been proposed. 
According to the first hypothesis oligometastases and 
polymetastases may have different phenotypes, determined 
by clonal populations with different metastatic potential. 
The second hypothesis suggests that metastatic process may 
be a continuum and oligometastatic disease is an early phase 
that can evolve in polymetastatic stage (28). 
In this report we present five cases of oligometastatic 
lung cancer, showing a long survival, after a multimodal 
treatment. In our cases the PFS ranges between 3 to 
65 months. All patients are still alive and progression free, 
with an OS ranging between 36 and 84 months. All patients 
underwent surgery for the primary tumor. 
Brain metastases were synchronous in four cases and 
in three of these were symptomatic (i.e., seizure, speech 
impairments, arm hypoesthesia and balance disorders). 
SR was performed in these three cases in order to relieve 
symptoms, while SRS alone or in association with WBRT 
was the selected therapeutic option for asymptomatic 
lesions. Only one patient with multiple symptomatic brain 
metastases received both surgical and radiation treatment. 
None received WBRT after surgery. The PFS and OS 
observed are surprisingly longer than those reported in the 
literature. These data are showed not only in patients with 
single metastasis and despite the classification of risk and 
prognosis according to Ashworth and Niibe-Onishi-Chang. 
In fact, only one of the cases we report is classified as poor 
risk or favorable prognosis (Table 1).
We performed a review of the last 5 years’ literature 
published on Medline (via PubMed—last search performed 
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on June 2016). We considered all the reports presenting 
data about oligometastatic NSCLC patients with brain 
metastases. We excluded the studies enrolling patients 
with various tumor types (8,11-13,27,29-34). As reported 
in Table 2, literature data are available from case reports, 
retrospective series and phase II trials. Very heterogeneous 
Table 2 Review of studies for oligometastatic lung cancer
Author Type of study
Pts  
(N)
Smoker Histology
Metastases 
site (pts)
Number of  
metastases
Treatment Survival (months) Publication 
yearPrimary tumor Metastases PFS OS 
Collen et al. 
(13)
Phase II 26 NR ADK =17; 
SC =2; 
other =7
Brain =6;  
bone =8;  
adrenal =6;  
lung =15;  
other =13
1–5 CRT =17;  
SBRT =9
SBRT 11.2 23.0 2014
De 
Ruysscher  
et al. (29)
Phase II 40 NR ADK =13; 
SC =9; 
other =18
Brain =17;  
bone =7;  
adrenal =4;  
lung =1;  
other =19
1–3 CRT =36;  
SBRT =2
SUR =9;  
SRS =11; 
SBRT =17
12.1 13.5;  
OS brain: 
13.6
2012
Gomez et al. 
(32)
Phase II R 49 NR NSCLC NR 1–3 CT =49 RT =13;  
CRT =7;  
SUR + RT =3; 
SUR =1
14.4 Not 
reached
2016
Arrieta et al. 
(12)
Retrospective 30 23 
(76.7%)
ADK =24; 
SC =4; 
other =2
Brain 1–5 CRT WBRT 8.4 31.8 2011
Griffioen  
et al. (11)
Retrospective 61 56 
(91.8%)
ADK =48; 
SC =5; 
other =8
Brain =36;  
bone =11;  
adrenal =4; 
lung =4;  
other =6
1–3 SUR =3;  
SUR + CT =3;  
SUR + CRT =3; 
CRT =40;  
RT =2;  
SBRT =10
SRS =18;  
SBRT =6;  
RT =13; 
WBRT =2;  
SUR =6;  
SUR + RT =16
6.6 13.5 2013
Enders et al. 
(30)
Retrospective 114 93 
(81.5%)
NR Brain >1 SUR; CT SUR; WBRT NR 11.2 2016
Fleckenstein 
et al. (33)
Retrospective 75 NR ADK =50; 
SC =17; 
other =8
Brain =51; 
bone =7; 
adrenal =34; 
lung =9;  
other =12
1–5 SUR =55;  
CRT =18;  
SBRT =2
SUR =12;  
SBRT/SRS/
hSRT =19; 
SUR + RT 
=49; RT =4
13.0 21.8 2016
Lamm et al. 
(31)
Case report 1 NR ADK Brain;  
brainstem; 
lung
2 brain;  
1 crbl;  
1 brainstem; 
1 lung
CRT SRS; SUR 5.0 >68.0 2012
Leduc et al. 
(34)
Case report 1 Yes ADK Brain;  
adrenal
2 brain;  
1 adrenal
SBRT SBRT 12.0 >30.0 2015
Yarchoan  
et al. (27)
Case report 1 Yes ADK Crbl; brain; 
adrenal;  
liver; lung
1 crbl;  
2 brain;  
1 adrenal;  
1 liver;  
1 lung
SUR + CT WBRT; SRS; 
SUR
5.0 >60.0 2015
Table 2 shows results of our published literature search on Medline (via PubMed) about the management of oligometastatic lung cancer in 
the last 5 years. Pts, patients; R, randomized; NR, not reported; ADK, adenocarcinoma; SC, squamous cell carcinoma; crbl, cerebellum; 
SUR, surgery; SRS, stereotactic radiosurgery; SBRT, stereotactic body radiation therapy; CRT, chemoradiotherapy; CT, chemotharapy; 
RT, radiotherapy; WBRT, whole brain radiotherapy; hSRT, hypofractionated stereotactic radiosurgery; PFS, progression free survival; OS, 
overall survival.
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Table 3 Ongoing trials
ClinicalTrials.gov 
identifier
Phase Intervention Status
NCT01781741 Pilot study SBRT after surgery Ongoing, not recruiting
NCT02450591 Pilot study Erlotinib followed by local treatment Recruiting
NCT01941654 II Local ablative therapy after EGFR TKI Recruiting
NCT01185639 II SBRT after CT Ongoing, not recruiting
NCT02054819 II CT and concurrent radiation to primary plus radiation therapy to metastatic site Recruiting
NCT02316002 II Pembrolizumab after curative intent treatment Recruiting
NCT01725165 II R Local treatment vs. maintenance CT after induction chemotherapy Ongoing, not recruiting
NCT00887315 II R CT vs. CT and hypofractionated image guided radiotherapy Terminated for slow accrual
NCT01796288 II R Second line erlotinib vs. erlotinib plus RT Recruiting
NCT00776100 II R Observation vs. radiation therapy after induction CT Completed
NCT01446744 II R SABR vs. palliative standard of care (CT or RT) Recruiting
NCT02417662 III CT vs. CT plus SABR Not yet open
NCT02076477 III CRT followed by CT vs. CT followed by CRT Recruiting
Table 3 shows all the completed, ongoing and not planned studies on the effectiveness of local treatments for oligometastatic lung 
cancer (source: clinicaltrials.gov—last search performed on June 2016). R, randomized; SBRT, stereotactic body radiation therapy; CT,  
chemotherapy; RT, radiotherapy; SABR, stereotactic ablative radiotherapy; CRT, chemoradiotherapy.
outcomes are reported, with OS ranging from 11.2 to over 
68 months. As expected, the better outcomes were described 
in case reports than in larger studies. Two retrospective 
series enrolled only patients with brain metastases. 
Nevertheless, they shown conflicting results, with a long 
OS of 31.8 months in Arrieta and colleagues’ series and a 
shorter OS (11.2 months) in Enders and colleagues’ report 
(12,30). A retrospective series published by Fleckenstein 
and colleagues addresses the relevance of synchronous 
vs. metachronous metastasis, not founding a prognostic 
relevance in this characteristic (33).
Interestingly, during the 2016 ASCO annual meeting 
the first randomized trial on oligometastatic NSCLC 
was presented. In this phase II study patients randomized 
to receive locoregional treatments showed a better PFS 
(14.4 months) than the control group (PFS 3.9 months) (32). 
Furthermore, treatment options are very heterogeneous, 
both for primary tumor and metastatic sites.
Since few data from randomized or homogeneous trials 
are currently available in literature, a growing interest in 
oligometastatic disease is observed. An increasing number 
of trials designed in order to study the effectiveness of local 
treatments (radiotherapy or surgery) are ongoing (Table 3). 
In particular, a phase III trial studying the best timing for 
chemotherapy and chemoradiotherapy (CRT) is ongoing 
(NCT02076477), and another phase III trial comparing 
chemotherapy alone vs. chemotherapy and stereotactic 
ablative radiotherapy (SABR) is open, but is not yet 
recruiting (NCT02417662).
Recent advances demonstrate a correlation between 
microRNA expression and oligometastatic stage (28,35,36). 
Lussier and colleagues identified certain microRNAs 
associated with a high rate of progression (HRP) and others 
with a low rate of progression (LRP) in NSCLC patients (36). 
Circulating tumor cells in oligometastatic patients are under 
investigation as well (NCT02949837). Further analyses are 
required. In fact, a better knowledge of tumor biology can 
help oncologists to identify patients with indolent disease, 
who could benefit from local treatment.
Conclusions
This case series confirms that oligometastatic NSCLC 
patients treated with locoregional aggressive therapies 
experience better outcomes and longer survivals. In fact, 
despite the evidence that stage IV NSCLC can benefit only 
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from palliative oncologic therapies, curative radiotherapy 
and surgery of the metastatic loci turned out to be a 
potential better therapeutic option for this subgroup of 
patients.
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